Navigation Links
Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO)
Date:9/26/2007

REDWOOD CITY, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced that results from a Phase 2 trial of glufosfamide plus gemcitabine were presented at the European Cancer Conference (ECCO) annual meeting in Barcelona, Spain.

In the Phase 2 clinical trial of glufosfamide in combination with gemcitabine for the treatment of advanced pancreatic cancer, six-month and one-year survival were 50% (95% CI: 31-67%) and 32% (95% CI: 16 - 49%), respectively. Median progression-free and overall survival were 3.7 and 6.0 months.

"We are encouraged by the results of this Phase 2 study, especially with respect to the one-year survival data which was higher than expected compared to previous studies of either gemcitabine alone or in combination with tarceva," said Barry Selick, Ph.D., chief executive officer of Threshold. "Based on these findings we believe that glufosfamide should have a role in the treatment of pancreatic cancer and, taken together with our Phase 3 results, we will be exploring the best options for its continued development in the treatment of this disease".

In a poster session at ECCO, Dr. Elena (Gabi) Chiorean, Indiana University Cancer Center, Indianapolis, IN, presented the Phase 2 results in a poster entitled, "Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma: results of a Phase 2 trial". In the clinical trial, 29 patients were treated, of which 28 patients with pancreatic adenocarcinoma previously untreated with chemotherapy were evaluated for response. Overall, 6 of 28 patients (21%; 95% CI: 8-41%) achieved a partial response including one unconfirmed partial response. Median duration of confirmed responses was 8.4 months. In addition, 11 of 28 patients (39%) experienced stable disease (duration 1.2+ to 12.6+ months). Objective response was assessed radiologically after every two cycles (8 weeks) of therapy. A partial response is characterized as a decrease in size by 30% of the sum of the longest diameters of target lesions, the absence of progression of all non-target lesions and no new lesions.

Grade 3 and 4 neutropenia occurred in 8 (28%) and 15 (52%) patients. Grade 3 and 4 thrombocytopenia occurred in 8 (28%) and 2 (7%) patients. Five patients (18%) had a glufosfamide-related serious adverse event (SAE), which included renal tubular acidosis (RTA) with renal failure (2 patients), RTA alone, vomiting or nausea. Three patients died from an SAE unrelated to glufosfamide. Another patient developed an SAE of renal failure after hypotension associated with pulmonary embolus. The creatinine clearance (CrCL) fell below 60 mL/min in 10 of 27 (37%) patients with CrCL greater than or equal to 60 at baseline.

These data indicate that glufosfamide plus gemcitabine may benefit patients with chemotherapy nave pancreatic adenocarcinoma. Hematologic and renal toxicity may be greater than would be expected with either agent alone although the small numbers preclude definitive conclusions. No unanticipated adverse events based on previous experience with glufosfamide were observed.

The Phase 2 poster is available on the Threshold website at http://investor.thresholdpharm.com/calendar.cfm.

About Glufosfamide

Glufosfamide combines the active part of ifosfamide, a member of a widely used class of chemotherapy drugs known as "alkylators", with a glucose molecule. Because of its glucose component and a tumor cell's increased need for glucose, glufosfamide may be preferentially transported into tumors compared to most normal tissues. Inside cells, the linkage between glucose and the alkylator is cleaved to release the active drug.

About Pancreatic Cancer

The American Cancer Society estimates that 37,170 patients will be diagnosed with pancreatic cancer in the United States in 2007, and approximately 33,370 patients will die from the disease. Only 15-20% of newly diagnosed patients are eligible for surgery, which is typically followed by radiation and chemotherapy. Patients with inoperable pancreatic cancer are treated with radiation and chemotherapy, or in the case of metastatic disease, chemotherapy alone as the advantages of radiation are reduced.

About Threshold Pharmaceuticals

Threshold is a biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer. By selectively targeting abnormally-proliferating tumor cells, the Company's drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional information, please visit our website (http://www.thresholdpharm.com).

Forward-Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, clinical trial progress and results, potential therapeutic uses and benefits of our product candidates and financial projections. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to commence, enroll or complete its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). The scientific information discussed in this news release related to our product candidate is preliminary and investigative. The product candidate is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidate. Only the FDA can determine whether the product candidate is safe and effective for the use(s) being investigated. Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on August 7, 2007 and is available from the SEC's website (http://www.sec.gov) and on our website (http://www.thresholdpharm.com) under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.

Contact:

Denise T. Powell

Sr. Director, Corporate Communications

Threshold Pharmaceuticals, Inc.

650-474-8206

dpowell@thresholdpharm.com


'/>"/>
SOURCE Threshold Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Calif. , April 28, 2016  Marking ... widely accessible breast and ovarian cancer risk test, ... panel analyzing 30 genes that highly impact the ... women. Available today, the Color Test analyzes hereditary ... prostate, stomach, and uterine cancers. The Color Test ...
(Date:4/28/2016)... 28, 2016 , Net Sales of $1.90 ... over the prior year period, and an increase of 1.2% ... Diluted EPS for the first quarter were $0.52 reported, a ... adjusted, an increase of 29.9% over the prior year period ... earnings guidance for 2016 Zimmer Biomet Holdings, Inc. ...
(Date:4/28/2016)... 28, 2016  ValGenesis, Inc., the market ... (VLMS) today announced that a prominent world ... of chronic kidney failure has selected ValGenesis ... corporate validation process. The global medical device ... to manage their validation processes electronically. Upon ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has selected Dr. ... gold in Rio. Under the care of Maximized Living doctors at the London ... unprecedented showing, Maximized Living is sending the largest contingent of elite chiropractors to Rio ...
(Date:4/29/2016)... , ... April 29, 2016 , ... In an ... and divorcee, shares her enthusiasm for Botox and lip injections, which she underwent in ... youth oriented Coachella Valley Music and Arts Festival. The article explains that Ms. Mirmelli’s ...
(Date:4/29/2016)... ... 29, 2016 , ... Shamangelic Healing, Sedona Arizona's Premier ... Alpha BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness to ... the store is just one more way Shamangelic Healing supports people’s quest for ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce is ... even security. Most importantly, employees are the single most important asset in creating ... so unhappy? , Just under half of American workers are emotionally checked out ...
(Date:4/29/2016)... ... April 29, 2016 , ... Conditions were ideal for Global ... Park on Sunday, with sunny skies, a light breeze and temperatures in the 60s. ... , The 5k Run and Walk and 1-mile walk were held to increase ...
Breaking Medicine News(10 mins):